# A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

> **NCT06010901** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 75 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** TQB2618 injection
- **DRUG:** Penpulimab injection
- **DRUG:** Anlotinib hydrochloride capsules

## Key facts

- **NCT ID:** NCT06010901
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-13
- **Primary completion:** 2025-03
- **Final completion:** 2025-07
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010901, "A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06010901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*